{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:28:28Z","timestamp":1790425708034,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Rare Trait Hope Fund"},{"name":"UNC TraCS Institute"},{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bowles Center for Alcohol Studies","award":["P60 AA011605"],"award-info":[{"award-number":["P60 AA011605"]}]},{"name":"Lineberger Comprehensive Center","award":["P30 CA016086"],"award-info":[{"award-number":["P30 CA016086"]}]},{"name":"Carolina Institute for Developmental Disabilities","award":["U54 HD079124"],"award-info":[{"award-number":["U54 HD079124"]}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ymthe.2020.11.012","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T21:50:42Z","timestamp":1605045042000},"page":"989-1000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Pre-clinical Gene Therapy with AAV9\/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation"],"prefix":"10.1016","volume":"29","author":[{"given":"Xin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Snanoudj-Verber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara S.","family":"Cathey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritva","family":"Tikkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.11.012_bib1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-016-0544-6","article-title":"Aspartylglycosaminuria: a review","volume":"11","author":"Arvio","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2020.11.012_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1651-2227.2002.tb01707.x","article-title":"Progressive nature of aspartylglucosaminuria","volume":"91","author":"Arvio","year":"2002","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymthe.2020.11.012_bib3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1067\/mpd.2001.110119","article-title":"Bone marrow transplantation for aspartylglucosaminuria: follow-up study of transplanted and non-transplanted patients","volume":"138","author":"Arvio","year":"2001","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ymthe.2020.11.012_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1096\/fasebj.14.2.361","article-title":"Enzyme replacement therapy in a mouse model of aspartylglycosaminuria","volume":"14","author":"Dunder","year":"2000","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2020.11.012_bib5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10545-010-9158-7","article-title":"Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice","volume":"33","author":"Dunder","year":"2010","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2020.11.012_bib6","doi-asserted-by":"crossref","first-page":"37583","DOI":"10.1038\/srep37583","article-title":"Identification of small molecule compounds for pharmacological chaperone therapy of aspartylglucosaminuria","volume":"6","author":"Banning","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.11.012_bib7","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bbadis.2017.12.014","article-title":"Amlexanox provides a potential therapy for nonsense mutations in the lysosomal storage disorder Aspartylglucosaminuria","volume":"1864","author":"Banning","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.ymthe.2020.11.012_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature15818","article-title":"Gene therapy returns to centre stage","volume":"526","author":"Naldini","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.11.012_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2016.09.011","article-title":"Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9","volume":"241","author":"Saraiva","year":"2016","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2020.11.012_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2016.02.013","article-title":"Viral vectors for therapy of neurologic diseases","volume":"120","author":"Choudhury","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ymthe.2020.11.012_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","article-title":"Development of intrathecal AAV9 gene therapy for giant axonal neuropathy","volume":"9","author":"Bailey","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.11.012_bib12","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/jnr.23882","article-title":"Intrathecal administration of AAV\/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant","volume":"94","author":"Karumuthil-Melethil","year":"2016","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.ymthe.2020.11.012_bib13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/gt.2011.130","article-title":"Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs","volume":"19","author":"Federici","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.11.012_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.11.012_bib15","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1089\/hum.2011.008","article-title":"Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery","volume":"22","author":"Snyder","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.11.012_bib16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.neuroscience.2011.06.080","article-title":"Local and retrograde gene transfer into primate neuronal pathways via adeno-associated virus serotype 8 and 9","volume":"193","author":"Masamizu","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.ymthe.2020.11.012_bib17","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1089\/hum.2012.218","article-title":"scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease","volume":"24","author":"Bucher","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.11.012_bib18","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1172\/JCI66778","article-title":"Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy","volume":"123","author":"Haurigot","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.11.012_bib19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1089\/hum.2013.005","article-title":"Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates","volume":"24","author":"Samaranch","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.11.012_bib20","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.012_bib21","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.012_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.11.012_bib23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene therapy for lysosomal storage diseases","volume":"13","author":"Sands","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.012_bib24","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/sj.gt.3300740","article-title":"Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse","volume":"5","author":"Peltola","year":"1998","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.11.012_bib25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/jgm.377","article-title":"Aspartylglucosaminidase (AGA) is efficiently produced and endocytosed by glial cells: implication for the therapy of a lysosomal storage disorder","volume":"5","author":"Harkke","year":"2003","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2020.11.012_bib26","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/nm1296-1375","article-title":"A mouse model for the human lysosomal disease aspartylglycosaminuria","volume":"2","author":"Kaartinen","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.11.012_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/hmg\/7.2.265","article-title":"Mice with an aspartylglucosaminuria mutation similar to humans replicate the pathophysiology in patients","volume":"7","author":"Jalanko","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.11.012_bib28","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/00005072-199812000-00007","article-title":"Monitoring the CNS pathology in aspartylglucosaminuria mice","volume":"57","author":"Tenhunen","year":"1998","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2020.11.012_bib29","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0002-9440(10)65674-X","article-title":"Progressive neurodegeneration in aspartylglycosaminuria mice","volume":"153","author":"Gonzalez-Gomez","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2020.11.012_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1005387215224","article-title":"Phenotypic characterization of mice with targeted disruption of glycosylasparaginase gene: a mouse model for aspartylglycosaminuria","volume":"21","author":"Kaartinen","year":"1998","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2020.11.012_bib31","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.11.012_bib32","doi-asserted-by":"crossref","first-page":"6684","DOI":"10.1093\/emboj\/16.22.6684","article-title":"Several cooperating binding sites mediate the interaction of a lysosomal enzyme with phosphotransferase","volume":"16","author":"Tikkanen","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2020.11.012_bib33","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1006\/abio.1993.1063","article-title":"A fluorometric assay for glycosylasparaginase activity and detection of aspartylglycosaminuria","volume":"208","author":"Mononen","year":"1993","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymthe.2020.11.012_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0014-2999(03)01272-X","article-title":"The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review","volume":"463","author":"Prut","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2020.11.012_bib35","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ymthe.2020.11.012_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.omtm.2017.04.006","article-title":"Improved MECP2 gene therapy extends the survival of MeCP2-null mice without apparent toxicity after intracisternal delivery","volume":"5","author":"Sinnett","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.11.012_bib37","first-page":"703","article-title":"Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection","volume":"61","author":"Bleyer","year":"1977","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.ymthe.2020.11.012_bib38","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/ijms18040706","article-title":"Functional analysis of the Ser149\/Thr149 variants of human aspartylglucosaminidase and optimization of the coding sequence for protein production","volume":"18","author":"Banning","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2020.11.012_bib39","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/sj.gt.3302134","article-title":"Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in\u00a0vivo","volume":"10","author":"McCarty","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.11.012_bib40","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.11.012_bib41","doi-asserted-by":"crossref","first-page":"4.17.1","DOI":"10.1002\/0471142301.ns0417s57","article-title":"Production of recombinant adeno-associated viral vectors and use in in\u00a0vitro and in\u00a0vivo administration","volume":"57","author":"Gray","year":"2011","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.ymthe.2020.11.012_bib42","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/srep00546","article-title":"Overstimulation of newborn mice leads to behavioral differences and deficits in cognitive performance","volume":"2","author":"Christakis","year":"2012","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.11.012_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fninf.2013.00015","article-title":"Fully automated rodent brain MR image processing pipeline on a Midas server: from acquired images to region-based statistics","volume":"7","author":"Budin","year":"2013","journal-title":"Front. Neuroinform."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620306109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620306109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:02:08Z","timestamp":1761501728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001620306109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1525001620306109"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.012","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-clinical Gene Therapy with AAV9\/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}